Clinical Trial Update: BT200 in Hereditary Bleeding Disorders [Phase 2]

View source ↗

Summary

Phase 2 trial update for BT200 in hereditary bleeding disorders has completed, investigating von Willebrand disease and Hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia
• Von Willebrand Disease

Drugs mentioned

• BT200 (Rondaptivon Pegol)

Snippet

Sponsor: Medical University of Vienna | Conditions: Von Willebrand Diseases, Hemophilia A | Phase 2 | Status: COMPLETED